RELB and extranodal nasal NK/T cell lymphoma: Moreover, BAY 11-7082 reduced gemcitabine sensitivity in NKTCL cells (Fig. 6E) and OE-RelB promoted gemcitabine sensitivity, which was inhibited by 2-DG treatment (Fig. 6F).